Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis
出版年份 2018 全文链接
标题
Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis
作者
关键词
-
出版物
DIABETES OBESITY & METABOLISM
Volume 20, Issue 6, Pages 1391-1398
出版商
Wiley
发表日期
2018-01-30
DOI
10.1111/dom.13235
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
- (2017) Amand F Schmidt et al. Lancet Diabetes & Endocrinology
- A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk
- (2016) Arihiro Kiyosue et al. AMERICAN JOURNAL OF CARDIOLOGY
- A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I
- (2016) Eli M. Roth et al. ATHEROSCLEROSIS
- Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial
- (2016) Michel Farnier et al. ATHEROSCLEROSIS
- Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
- (2016) Henry N. Ginsberg et al. CARDIOVASCULAR DRUGS AND THERAPY
- Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein MetabolismClinical Perspective
- (2016) Gerald F. Watts et al. CIRCULATION
- No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies
- (2016) Helen M. Colhoun et al. EUROPEAN HEART JOURNAL
- Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients
- (2016) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association Between Low-Density Lipoprotein Cholesterol–Lowering Genetic Variants and Risk of Type 2 Diabetes
- (2016) Luca A. Lotta et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease
- (2015) Sha Li et al. ANNALS OF MEDICINE
- Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
- (2015) Xin-Lin Zhang et al. BMC Medicine
- A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins
- (2015) Joseph L. Goldstein et al. CELL
- Using Genetic Variants to Assess the Relationship Between Circulating Lipids and Type 2 Diabetes
- (2015) Tove Fall et al. DIABETES
- Association Between Familial Hypercholesterolemia and Prevalence of Type 2 Diabetes Mellitus
- (2015) Joost Besseling et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- PCSK9: A key factor modulating atherosclerosis
- (2015) Sha Li et al. Journal of Atherosclerosis and Thrombosis
- Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial
- (2015) Harold Bays et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk
- (2015) Yascara G. Luna Saavedra et al. Journal of Clinical Lipidology
- HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials
- (2015) Daniel I Swerdlow et al. LANCET
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- PCSK9 and lipid lowering drugs
- (2014) Yuan-Lin Guo et al. CLINICA CHIMICA ACTA
- Statins and the Risk of Diabetes: Evidence From a Large Population-Based Cohort Study
- (2014) Giovanni Corrao et al. DIABETES CARE
- Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial
- (2014) Eli M. Roth et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
- (2014) Dirk J. Blom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia
- (2012) Frederick Raal et al. CIRCULATION
- Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
- (2012) James M. McKenney et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
- (2012) Michael J Koren et al. LANCET
- Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
- (2012) Evan A Stein et al. LANCET
- Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
- (2012) Eli M. Roth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dyslipidemias in the Prevention of Cardiovascular Disease: Risks and Causality
- (2012) Ian Graham et al. Current Cardiology Reports
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
- (2010) Naveed Sattar et al. LANCET
- PCSK9 is expressed in pancreatic δ-cells and does not alter insulin secretion
- (2009) Cédric Langhi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities
- (2009) Majambu Mbikay et al. FEBS LETTERS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started